NEW YORK (GenomeWeb News) – Sequenom said in its Form 10-K filed with the US Securities and Exchange Commission this week that the US Patent and Trademark Office on March 12 declared a patent interference between US Patent No. 8,008,018 held by Verinata Health, now part of Illumina, and Sequenom's pending patent application No. 13/070,275. In February 2012, Verinata and Stanford University sued Sequenom alleging it infringes the patent through the offering of its MaterniT21 Plus test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

Jun
23
Sponsored by
PerkinElmer

This webinar will demonstrate how automated liquid handling workstations can reduce bottlenecks in library preparation for next-generation sequencing, enabling scientific advances in genomics research that were not possible five years ago.